Who
Mark G. Foletta
Director
Company insider
Files Form 4 as: Director, DexCom; Director, AMN Healthcare Services; Director, Enanta Pharmaceuticals; EVP & Chief Financial Officer, Forte Biosciences; Director, Regulus Therapeutics; Interim CFO, Biocept; Director, Ambit Biosciences; SVP, Chief Financial Officer, Amylin Pharmaceuticals.
In numbers
- Trades disclosed
- 384
- Buys
- 4
- Sells
- 55
- Bought
- $176K
- Sold
- $10.4M
- Companies
- 9
- Companies where not an officer
- 6
- First trade
- 17 Jan 2006
- Last trade
- 3 Aug 2026
- Last filed
- 4 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Aug 2026filed 4 Aug 2026 | DXCM DexComMedical Devices | SEC FORM 4 Sold | $171K2,000 at $85.32 | filing |
| 3 Aug 2026filed 4 Aug 2026 | DXCM DexComMedical Devices | SEC FORM 4 Sold | $171K2,000 at $85.32 | filing |
| 31 Jul 2026filed 4 Aug 2026 | DXCM DexComMedical Devices | SEC FORM 4 Sold | $160K2,000 at $80.00 | filing |
| 31 Jul 2026filed 4 Aug 2026 | DXCM DexComMedical Devices | SEC FORM 4 Sold | $160K2,000 at $80.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | DXCM DexComMedical Devices | SEC FORM 4 Sold | $282K3,801 at $74.10 | filing |
| 15 Jun 2026filed 17 Jun 2026 | DXCM DexComMedical Devices | SEC FORM 4 Sold | $15K199 at $74.82 | filing |
| 15 Jun 2026filed 17 Jun 2026 | DXCM DexComMedical Devices | SEC FORM 4 Sold | $282K3,801 at $74.10 | filing |
| 15 Jun 2026filed 17 Jun 2026 | DXCM DexComMedical Devices | SEC FORM 4 Sold | $15K199 at $74.82 | filing |
| 15 Jun 2026filed 17 Jun 2026 | AMN AMN Healthcare ServicesProfessional Services | SEC FORM 4 Sold | $52K1,681 at $31.07 | filing |
| 15 Jun 2026filed 17 Jun 2026 | AMN AMN Healthcare ServicesProfessional Services | SEC FORM 4 Sold | $62K2,000 at $31.07 | filing |
| 15 Jun 2026filed 17 Jun 2026 | AMN AMN Healthcare ServicesProfessional Services | SEC FORM 4 Sold | $52K1,681 at $31.07 | filing |
| 15 Jun 2026filed 17 Jun 2026 | AMN AMN Healthcare ServicesProfessional Services | SEC FORM 4 Sold | $62K2,000 at $31.07 | filing |
| 28 May 2026filed 1 Jun 2026 | DXCM DexComMedical Devices | SEC FORM 4 Code A | —6,331 at $0.00 | filing |
| 28 May 2026filed 1 Jun 2026 | DXCM DexComMedical Devices | SEC FORM 4 Code A | —6,331 at $0.00 | filing |
| 8 May 2026filed 11 May 2026 | DXCM DexComMedical Devices | SEC FORM 4 Code G | —5,731 at $0.00 | filing |
| 8 May 2026filed 11 May 2026 | DXCM DexComMedical Devices | SEC FORM 4 Code G | —5,731 at $0.00 | filing |
| 8 May 2026filed 11 May 2026 | DXCM DexComMedical Devices | SEC FORM 4 Code G | —5,731 at $0.00 | filing |
| 8 May 2026filed 11 May 2026 | DXCM DexComMedical Devices | SEC FORM 4 Code G | —5,731 at $0.00 | filing |
| 1 May 2026filed 4 May 2026 | AMN AMN Healthcare ServicesProfessional Services | SEC FORM 4 Code M | —8,325 at $0.00 | filing |
| 1 May 2026filed 4 May 2026 | AMN AMN Healthcare Servicesoption or derivative · Professional Services | SEC FORM 4 Code M | —8,325 at $0.00 | filing |
News
Vontobel Holding Ltd. Sells 14,970 Shares of DexCom, Inc. $DXCMDXCM · dailypolitical.com · 20 Oct 2026
0 headlines in the last 90 days name Mark G. Foletta; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.